Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AMLX - US03237H1014 - Common Stock

15.2 USD
+0.38 (+2.56%)
Last: 11/25/2025, 9:50:06 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AMLX. AMLX was compared to 192 industry peers in the Pharmaceuticals industry. While AMLX has a great health rating, there are worries on its profitability. While showing a medium growth rate, AMLX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AMLX has reported negative net income.
In the past year AMLX has reported a negative cash flow from operations.
In the past 5 years AMLX reported 4 times negative net income.
In the past 5 years AMLX reported 4 times negative operating cash flow.
AMLX Yearly Net Income VS EBIT VS OCF VS FCFAMLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

AMLX has a Return On Assets of -41.15%. This is comparable to the rest of the industry: AMLX outperforms 44.27% of its industry peers.
AMLX has a Return On Equity (-44.96%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.15%
ROE -44.96%
ROIC N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
AMLX Yearly ROA, ROE, ROICAMLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMLX Yearly Profit, Operating, Gross MarginsAMLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMLX has more shares outstanding
There is no outstanding debt for AMLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMLX Yearly Shares OutstandingAMLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
AMLX Yearly Total Debt VS Total AssetsAMLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

AMLX has an Altman-Z score of 27.73. This indicates that AMLX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.73, AMLX belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.73
ROIC/WACCN/A
WACC8.89%
AMLX Yearly LT Debt VS Equity VS FCFAMLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 13.70 indicates that AMLX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.70, AMLX belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
AMLX has a Quick Ratio of 13.70. This indicates that AMLX is financially healthy and has no problem in meeting its short term obligations.
AMLX has a Quick ratio of 13.70. This is amongst the best in the industry. AMLX outperforms 84.38% of its industry peers.
Industry RankSector Rank
Current Ratio 13.7
Quick Ratio 13.7
AMLX Yearly Current Assets VS Current LiabilitesAMLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

AMLX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.70%.
Looking at the last year, AMLX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, AMLX shows a very strong growth in Revenue. The Revenue has been growing by 127.75% on average per year.
EPS 1Y (TTM)2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.42%
Revenue 1Y (TTM)-100%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%-100%

3.2 Future

AMLX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.34% yearly.
The Revenue is expected to grow by 24.82% on average over the next years. This is a very strong growth
EPS Next Y30.54%
EPS Next 2Y18.24%
EPS Next 3Y10.99%
EPS Next 5Y17.34%
Revenue Next Year-100%
Revenue Next 2Y-96.97%
Revenue Next 3Y-28.04%
Revenue Next 5Y24.82%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AMLX Yearly Revenue VS EstimatesAMLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AMLX Yearly EPS VS EstimatesAMLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMLX Price Earnings VS Forward Price EarningsAMLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMLX Per share dataAMLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.24%
EPS Next 3Y10.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYLYX PHARMACEUTICALS INC

NASDAQ:AMLX (11/25/2025, 9:50:06 AM)

15.2

+0.38 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners71.5%
Inst Owner Change30.72%
Ins Owners7.77%
Ins Owner Change-0.56%
Market Cap1.62B
Revenue(TTM)N/A
Net Income(TTM)-149.28M
Analysts85.88
Price Target20.74 (36.45%)
Short Float %11.6%
Short Ratio5.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.03%
Min EPS beat(2)-1.31%
Max EPS beat(2)19.37%
EPS beat(4)2
Avg EPS beat(4)6.92%
Min EPS beat(4)-3.7%
Max EPS beat(4)19.37%
EPS beat(8)3
Avg EPS beat(8)-243.6%
EPS beat(12)6
Avg EPS beat(12)-137.24%
EPS beat(16)7
Avg EPS beat(16)-138.3%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)36.69%
PT rev (3m)74.91%
EPS NQ rev (1m)7.39%
EPS NQ rev (3m)20.55%
EPS NY rev (1m)1.04%
EPS NY rev (3m)8.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.88
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.15%
ROE -44.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.7
Quick Ratio 13.7
Altman-Z 27.73
F-Score3
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)1551.62%
Cap/Depr(5y)4086.74%
Cap/Sales(3y)17.77%
Cap/Sales(5y)40.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.42%
EPS Next Y30.54%
EPS Next 2Y18.24%
EPS Next 3Y10.99%
EPS Next 5Y17.34%
Revenue 1Y (TTM)-100%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-96.97%
Revenue Next 3Y-28.04%
Revenue Next 5Y24.82%
EBIT growth 1Y-30.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.05%
EBIT Next 3Y14.57%
EBIT Next 5YN/A
FCF growth 1Y-192.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-200.9%
OCF growth 3YN/A
OCF growth 5YN/A

AMYLYX PHARMACEUTICALS INC / AMLX FAQ

What is the fundamental rating for AMLX stock?

ChartMill assigns a fundamental rating of 4 / 10 to AMLX.


Can you provide the valuation status for AMYLYX PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to AMYLYX PHARMACEUTICALS INC (AMLX). This can be considered as Overvalued.


Can you provide the profitability details for AMYLYX PHARMACEUTICALS INC?

AMYLYX PHARMACEUTICALS INC (AMLX) has a profitability rating of 1 / 10.